SAN ANTONIO — A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR Sa…
A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. T…
Adding docetaxel to the most commonly used combination chemotherapy improved tumor regression rate, delayed tumor growth and prolonged survival for patients with advanced stomach cancer, according to interim results of a Phase III international clinical trial presented at the annual meeting of the American Society of Clinical Oncology.
New research suggests that combining the chemotherapy drug paclitaxel with very low doses of the HIV-fighting drug AZT may shrink or even eradicate certain types of cancer tumors. Using both drugs in mice helped inhibit the enzyme telomerase, a component critical to the livelihood of some cancer cells. Telomerase helps to build and maintain telomeres ? protective strands of DNA at each end of a chromosome.
A new implantable device has been found to reduce the risk of death from congestive heart failure by 40 percent, triggering the early halt of a national trial of the device. “This trial was the largest one in history to test an implanted pacemaker or defibrillator, and it represents a landmark study for the treatment of congestive heart failure,” says Mitchell N. Faddis, M.D., Ph.D., assistant professor of medicine at Washington University School of Medicine in St. Louis. “I think this is one of the most important therapies developed in the last decade for treatment of severe heart disease.”